

1 Title: Post COVID-19 condition of the Omicron variant of SARS-CoV-2

2

3 Shinichiro Morioka^{1,2,3}, Shinya Tsuzuki^{3,4}, Michiyo Suzuki¹, Mari Terada^{1,5}, Masako

4 Akashi¹, Yasuyo Osanai¹, Chika Kuge¹, Mio Sanada¹, Keiko Tanaka¹, Taketomo

5 Maruki¹, Kozue Takahashi¹, Sho Saito¹, Kayoko Hayakawa^{1,3}, Katsuji Teruya⁶,

6 Masayuki Hojo⁷, Norio Ohmagari^{1,3}

7

8 ¹Disease Control and Prevention Center, National Center for Global Health and

9 Medicine Hospital, Tokyo, Japan

10 ²Emerging and Reemerging Infectious Diseases, Graduate School of Medicine, Tohoku

11 University, Sendai, Japan

12 ³AMR Clinical Reference Center, National Center for Global Health and Medicine

13 Hospital, Tokyo, Japan

14 ⁴Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium

15 ⁵Center for Clinical Sciences, National Center for Global Health and Medicine, Tokyo,

16 Japan

17 ⁶AIDS Clinical Center, National Center for Global Health and Medicine Hospital,

18 Tokyo, Japan

19 ⁷Division of Respiratory Medicine, National Center for Global Health and Medicine

20 Hospital, Tokyo, Japan

21

22 Key words: Post COVID-19 conditions, Long COVID, omicron, WHO definition

23

24 Running title: Post COVID-19 conditions of Omicron

25

26 Corresponding author:

27 Shinichiro Morioka

28 Address: 1-21-1 Toyama, Shinjuku-ku, Tokyo 162-8655, Japan

29 Telephone: +81-3-3202-7181

30 Fax: +81-3-6228-0738

31 E-mail: shmorioka@hosp.ncgm.go.jp

32

33 **Abstract**

34 **Background:** No epidemiological data on post coronavirus disease (COVID-19)

35 condition due to Omicron variant has been reported yet.

36 **Methods:** This was as a single-center, cross-sectional study, that interviewed via

37 telephone the patients who recovered from Omicron COVID-19 infection (Omicron

38 group), and surveyed via self-reporting questionnaire those patients infected with other

39 strains (control group). Data on patients' characteristics, information regarding the

40 acute-phase COVID-19, as well as presence and duration of COVID-19-related

41 symptoms were obtained. Post COVID-19 condition in this study was defined as a

42 symptom that lasted at least 2 months within 3 months since the onset of COVID-19.

43 We investigated and compared the prevalence of post COVID-19 condition in both

44 groups after performing propensity score matching.

45 **Results:** We conducted interviews for 53 out of 128 patients with Omicron, and

46 obtained 502 responses in the control group. After matching, 18 patients each in

47 Omicron and control group had improved covariate balance of the older adult, female

48 sex, obese patients, and vaccination status. There were no significant differences in the

49 prevalence of each post-acute COVID-19 symptoms between the two groups. The

50 numbers of patients with at least one post-acute COVID-19 symptom in the Omicron

51 and the control group were 1 (5.6%) and 10 (55.6%) ($p=0.003$), respectively.

52 **Conclusion:** The prevalence of post Omicron COVID-19 conditions was less than that

53 of the other strains. Further research with more participants is needed to investigate the

54 precise epidemiology of post COVID-19 condition of Omicron, and its impact on

55 health-related quality of life and social productivity.

56

57

58 **Introduction**

59 Coronavirus disease (COVID-19) has become a global pandemic with 513
60 million cumulative cases and 6.2 million deaths worldwide as of May 4, 2022 [1].
61 Following the onset of COVID-19, 49% of patients had at least one prolonged symptom,
62 lasting more than 12 months [2]. These post-acute sequelae of severe acute respiratory
63 syndrome coronavirus 2 (SARS-CoV-2) infection are known as the post COVID-19
64 condition or long COVID [3][4]. Studies have shown that the common symptoms of the
65 post COVID-19 condition included fatigue, shortness of breath, dysosmia, hair loss and
66 cognitive impairment, and multiple symptoms often overlap and persist [2, 5, 6].

67 A prospective longitudinal observational study revealed the difference in the
68 prevalence of acute-phase symptoms in patients with Omicron and Delta variants of
69 SARS-CoV-2 [7]. In particular, sore throat was more common in Omicron than in Delta,
70 while loss of smell was infrequent in Omicron than Delta. However, no epidemiological
71 data on post COVID-19 condition of Omicron has been reported yet. Considering that
72 many patients were infected with Omicron variant worldwide [8][9], several patients
73 may suffer from post COVID-19 condition due to Omicron. In this study, we aimed to
74 investigate and compare the prevalence of the post COVID-19 condition of omicron
75 with that of the other strains.

76

77 **Methods**

78 This study was a single-center, cross-sectional study, using telephone interviews

79 and a self-reporting questionnaire survey for the omicron and control group, respectively.

80 The patients in telephone and self-reported survey provided an oral and written informed

81 consent, respectively. This study was reviewed and approved by the ethics committee of

82 the Center Hospital of the National Center for Global Health and Medicine (NCGM)

83 (NCGM-G-004406-00, NCGM-G-004439-00).

84

85 **Study participants and study period**

86 *Omicron group*

87 Patients who were admitted due to COVID-19 at the National Center for

88 Global Health and Medicine (NCGM) between December 1, 2021 and February 9, 2022

89 were invited for telephone interviews. The patients were positive for SARS-CoV-2

90 E484A mutation, and negative for L452R mutation, as confirmed by the reverse

91 transcription-polymerase chain reaction (rtPCR).

92 Patients who died during admission were excluded from the study. The

93 telephone interviews were conducted from April 14, 2022 to April 26, 2022 after

94 confirming that 3 months had passed since the onset of COVID-19 symptoms for each
95 patient. The investigators (M Suzuki, M Sanada, MA, YO, MT, KT, CK, TM)
96 administered a one-on-one structured telephone interviews with the patients using an
97 interview guide (Appendix 1). The interview lasted for 5-10 minutes, and each patient
98 was interviewed only once. The investigators were nurses, researchers, and physicians
99 working in the NCGM. In the individual telephone interviews, the participants were
100 asked regarding their symptoms and the duration, and were recorded by checking the
101 electronic files. If the participants were unable to recall the symptom duration, the
102 answers were regarded as missing values.

103

104 *Control group*

105 The participants recruited in the control group were patients who recovered from
106 COVID-19, and who visited the outpatient service of the Disease Control and Prevention
107 Center in the NCGM between February 2020 and November 2021 to undergo a
108 pre-donation screening test for COVID-19 convalescent plasmapheresis [6]. All
109 participants in this study were Japanese since the screening test was designed only for
110 Japanese patients. Most of the participants had received acute-phase treatment for
111 COVID-19 in other hospitals. A self-reporting, online or paper-based questionnaire was

112 sent to eligible patients in February 2022, without any reminders (Appendix 2).

113 Participation in this survey was voluntary, but not anonymous. The participants were

114 requested to complete and return the questionnaire.

115 We developed the questionnaire based on previous similar studies [2, 5, 6,

116 10-15], including findings from our previous work on prolonged and late-onset

117 symptoms of COVID-19 [16]. We attempted to minimize the number of questions

118 required to maximize the response rate. Six non-medical employees in NCGM were

119 included in the pilot testing. They provided feedback on the content, clarity, and format of

120 the items, as well as whether the survey questions were self-explanatory. Revisions were

121 made on the questionnaire according to their feedback.

122

123 *Items investigated*

124 Information obtained included age, sex, ethnicity, smoking history, body mass

125 index (BMI), underlying medical conditions, COVID-19 vaccination status, details on

126 acute phase of COVID-19, as well as presence and duration of symptoms of post

127 COVID-19 condition. Disease severity based on previous literature [2, 12] was

128 categorized as follows: 1) mild, no oxygen therapy; 2) moderate, oxygen therapy without

129 mechanical ventilation; and 3) severe, mechanical ventilation with or without

130 extracorporeal membrane oxygenation.

131

132 *Definition of post COVID-19 condition*

133 The definition of post COVID-19 condition in this study was a symptom that

134 persisted for at least 2 months within 3 months since the onset of COVID-19. The post

135 COVID-19 condition included fatigue, shortness of breath, cough, dysosmia (including

136 anosmia), dysgeusia (including ageusia), hair loss, depressed mood, brain fog, loss of

137 concentration, and memory disturbance. Since this study did not include patient

138 consultations, it could not be ascertained whether the symptoms were due to COVID-19

139 or an alternative diagnosis [3].

140

141 *Statistical analysis*

142 The patient characteristics, presence of pneumonia, disease severity, and

143 treatment in the acute phase of COVID-19 were expressed as median and interquartile

144 range (IQR) for continuous variables, and as absolute values (n) with % for categorical

145 variables.

146 A multivariable logistic regression model was developed to estimate a
147 propensity score for being the Omicron group. Age (older adult), sex (female), BMI \geq
148 25 and vaccination status (vaccinated at least twice at the time of the survey) were
149 included in the model as the four factors were associated with increased risk of post
150 COVID-19 condition [17, 18]. Propensity score matching (PSM) was performed using
151 the nearest neighbor matching with a caliper width of 0.2 [19]. The standardized
152 difference was used to measure covariate balance, and an absolute standardized
153 difference above 10% was interpreted as a meaningful imbalance. Subsequently, the
154 proportion of patients with prolonged symptoms, and those with symptoms lasting at least
155 2 months within 3 months since the onset have been described among the matched
156 population.

157 The level of significance in all statistical tests was set at $\alpha = 0.05$. Data were
158 analyzed using SPSS[®] Statistics version 25.0 software (IBM[®], Armonk, NY, USA) and
159 R, version 4.1.3 (R Foundation for Statistical Computing; 2018, Vienna, Austria).

160

161 **Results**

162 *Omicron group*

163 A total of 128 patients were potentially eligible for telephone interviews. Of
164 whom, one died after discharge. Four opted not to participate, while interviews could
165 not be done in 22 patients due to medical condition such as dementia, and in one patient
166 due to language barrier. Meanwhile, 47 patients could not be contacted via telephone.
167 Overall, 53 patients were included and completed the interviews.

168

169 *Control group*

170 A self-reporting questionnaire was sent to 1148 patients (958 online; patients;
171 190 paper-based) who had recovered from COVID-19. Of which, 502 responses (413
172 online;89 paper-based) were obtained. The overall response rate was 43.7% (43.1%
173 online; 46.8% paper-based). Among the 502 patients, 133 (31.5%), 205 (48.6%), and 84
174 (19.9%) (80 missing) got infected with COVID-19 between February 2020 and October
175 2020, November 2020 and June 2021 (Alpha strains predominant), and July 2021 and
176 October 2021 (Delta strains predominant), respectively[8][20].

177

178 *Characteristics of the participants in the Omicron and the control group before and after*

179 *PSM*

180 The characteristics of the participants in the Omicron and the control group
181 before and after PSM are summarized in **Table 1** and **Table 2**, respectively. Before
182 matching, the mean ages (years, interquartile range: IQR) and mean BMI (IQR) in the
183 Omicron and the control group were 56.0 (35.0, 69.5) and 48.0 (42.0, 55.0), and 24.4
184 (22.2, 26.8) and 23.1 (20.7, 25.9), respectively. Fourteen patients (26.4%) in the
185 Omicron group and 300 patients (59.8%) in the control group were women. Forty-five
186 patients (84.9%) in the Omicron group and 11 patients (2.2%) in the control group tested
187 positive for SARS-CoV-2 at least seven days after their second COVID-19 vaccination
188 when immunity had developed [21]. Forty-two patients (79.2%) in the Omicron group
189 and 393 patients (86.4%) in the control group had mild disease. Missing values ranged
190 from 0% to 15.5%.

191 After matching, 18 patients each in the Omicron and control group had
192 improved covariate balance. The number of the older adults (defined as age of 65 and
193 above), female, obese (defined as BMI \geq 25), and vaccinated patients (defined as
194 patients who tested positive for SARS-CoV-2 at least seven days after their second
195 vaccination) were 4 (22.2%) (standardized mean difference: SMD $<$ 0.001, $p=1.000$), 10
196 (55.6%) (SMD $<$ 0.001, $p=1.000$), 5 (27.8%) (SMD $<$ 0.001, $p=1.000$), and 10 (55.6%)
197 (SMD $<$ 0.001, $p=1.000$), respectively for both the Omicron and the control group.

198

199 *Prevalence of post COVID-19 condition in the Omicron group and the control group*

200 The prevalence of post COVID-19 condition in the Omicron and the control
201 group before matching is summarized in **Table 3** and **Appendix 3**, respectively. In the
202 Omicron group, 3 (5.7%) patients suffered from fatigue, 2 (3.8%) from shortness of
203 breath, 2 (3.8%) from cough, 2 (3.8%) from depressed mood, and 3 patients (5.7%)
204 from loss of concentration that lasted more than 2 months within 3 months since the
205 disease onset. As for the other symptoms of the Omicron group, 45 (84.9%) patients had
206 fever, 30 (56.6%) had sore throat, and 15 (28.3%) had runny nose in the acute phase.
207 However, none of the symptoms lasted more than 2 months within 3 months since the
208 disease onset. In addition, 3 patients (5.7%) had dysosmia, and 7 (13.2%) had
209 dysgeusia.

210 The prevalence of post COVID-19 condition in the Omicron and the control
211 group after matching is summarized in **Table 4**. There were no significant differences in
212 the prevalence of each post-acute COVID-19 symptom between the two groups. The
213 number of patients with at least one post-acute COVID-19 symptoms in the Omicron
214 and the control group were 1 (5.6%) and 10 (55.6%) ($p=0.003$), respectively. The
215 frequency and duration of each symptom in the Omicron and the control group are

216 shown in **Appendix 4** and **Appendix 5**, respectively. The frequency and duration of at
217 least one symptom in both groups are shown in **Figure 1**. The number of patients with at
218 least one symptom at 60 and 90 days after symptom onset or diagnosis of COVID-19 in
219 the Omicron group were 1 (5.6%) and 1 (5.6%), respectively. Meanwhile, 12 (66.7%)
220 and 7 (38.9%) patients in the control group had at least one symptom that lasted at 60
221 and 90 days, respectively.

222

223 **Discussion**

224 In this study, we investigated and compared the prevalence of post COVID-19
225 condition in patients with Omicron variant and the previous strains after performing
226 PSM. Since we matched on age, sex, BMI and vaccination status, these factors are
227 unlikely to confound our observation on the prevalence of post COVID-19 condition
228 [17, 18]. The main finding of this study was that there were no significant differences in
229 the prevalence of post COVID-19 conditions between the Omicron and the control
230 group although the prevalence in the Omicron group tended to be less than that in the
231 control group. In addition, the number of patients with at least one post-acute
232 COVID-19 symptom in the Omicron group was significantly less than that in the
233 control group. However, several patients were infected with Omicron variants

234 worldwide. In particular, World Health Organization reported that among the 432,470
235 specimens collected from 13 January to 11 February 2022, 98.3% were Omicron variant
236 [9]. Thus, while the prevalence rate may be lower in Omicron group, the actual number
237 of patients suffering from post COVID-19 condition can be high. Further research with
238 several participants is needed to investigate the precise epidemiology of post COVID-19
239 conditions due to Omicron, and assess its impact on health-related quality of life and
240 social productivity.

241 We found that 84.9%, 56.6%, and 28.3% of patients with Omicron had fever,
242 sore throat, and runny nose, respectively, but none of which lasted more than 2 months
243 within 3 months since the onset of the disease. Cristina Menni et al. reported that sore
244 throat was more common with Omicron than with Delta variant (70.5% vs 60.8%, odds
245 ratio 1.55; 95% CI 1.43–1.69, $p < 0.001$) [7], indicating that patients with Omicron
246 tended to have upper respiratory symptoms. This is also consistent with an *in vitro* study
247 stating that Omicron replicates faster than all other SARS-CoV-2 variants in the
248 bronchus but less efficiently in the lung parenchyma, and appears to enter human cells
249 by a different route [22]. Although we could not compare the prevalence and duration of
250 these symptoms of Omicron with those of previous strains, characterizing the clinical
251 course of infection by Omicron is not only of direct public health relevance providing

252 public and clinicians awareness on what symptoms to look out for, but will also assist in
253 understanding the potential effects of future variants of concern [7].

254 We also found that 5.7%, 13.2% and 3.8% of the patients with Omicron had
255 dysosmia, dysgeusia, and hair loss, respectively. This finding was consistent with a
256 previous report stating that loss of smell was less common in participants infected with
257 Omicron than with Delta variant (16.7% vs 52.7%, odds ratio 0.17; 95% CI 0.16–0.19,
258 $p < 0.001$) [7]. These findings can also help raise awareness on what symptoms are more
259 common with the Omicron variant to that can aide in rapid diagnosis, minimizing the
260 spread of COVID-19.

261 Our study had several limitations. First, we compared data obtained from two
262 surveys with different methodologies: data of Omicron group from telephone interviews,
263 and those of control group from a self-reported questionnaire-based online/paper-based
264 survey, which may have influenced the results. Second, those with more severe
265 symptoms might less likely to respond to telephone calls if they were subsequently
266 hospitalized, making data on the critically ill more likely to be scarce. Third, the
267 self-reported questionnaire-based online/paper-based survey was subject to various
268 biases, such as selection, volunteer, and recall biases. In particular, the survey was limited
269 to COVID-19 convalescent plasmapheresis patients who underwent the pre-donation

270 screening test. It is unclear whether the results of this survey can be applied to all patients
271 recovering from COVID-19. Fourth, this was a single-center study with a small sample
272 size. Fifth, the definition of post COVID-19 condition in this study was similar to a
273 previous study [3]. However, whether the symptoms could be explained by an
274 alternative diagnosis remains unclear in our study. Therefore, our findings may have
275 overestimated the prevalence of post COVID-19 condition. Sixth, some patients had
276 persistent symptoms at the time of the survey. In these cases, the actual duration of the
277 symptoms was unclear. Long-term observation is needed to better understand the
278 duration of post-COVID conditions of Omicron. Seventh, it was impossible to determine
279 the type of variant in the control group. Considering that 31.5%, 48.6%, and 19.9% in the
280 control group got infected with COVID-19 between February 2020 and October 2020,
281 November 2020 and June 2021, and July 2021 and October 2021, respectively, it was
282 likely that alpha (B.1.1.7) strains were most predominant [25][26][27]. The prevalence of
283 the SARS-CoV-2 variants may have influenced the frequency of post-COVID conditions
284 in the control group. Lastly, we could not identify each variant in Omicron (B.1.1.529,
285 BA.1, BA.1.1, BA.2, BA.3, BA.4 and BA.5 lineages).

286

287 **Conclusion**

288 We investigated the prevalence of post COVID-19 conditions in patients with
289 Omicron and other strains of SARS-CoV-2 after matching on age, sex, BMI, and
290 vaccination status. There were no significant differences in the prevalence of each
291 post-acute COVID-19 symptom between the Omicron and the control group. However,
292 the number of patients with at least one post-acute COVID-19 symptom in the Omicron
293 group was significantly less than that in the control group. As many patients worldwide
294 were infected with Omicron, several patients may suffer from post-acute COVID-19
295 symptoms. Further research with more participants is needed to investigate more precise
296 epidemiology of post COVID-19 condition due to Omicron, and its impact on
297 health-related quality of life and social productivity.

298

299

300 **Acknowledgments**

301 We thank all the people who participated in our study.

302

303 **Funding**

304 This work was supported by the Health, Labor and Welfare Policy Research Grants,

305 Research on Emerging and Reemerging Infectious Diseases and Immunization (grant

306 number 20HA1006).

307

308 **Conflicts of interest**

309 All authors report no conflicts of interest relevant to this article.

310

311

312 **References**

- 313 1. COVID-19 Dashboard, World Health Organization.
314 <https://www.gavi.org/covid19/dashboard?gclid=CjwKCAjwjtOTBhAvEiwASG4bCJqe>
315 [6lbmoeoTy14wqJZsAW52-Jqd7HdYU4UUK7-IeVE8zEtoA3hmYxoCkG8QAvD_Bw](https://www.gavi.org/covid19/dashboard?gclid=CjwKCAjwjtOTBhAvEiwASG4bCJqe)
316 E [accessed 7 May 2022]
- 317 2. Huang, L., et al., *1-year outcomes in hospital survivors with COVID-19: a longitudinal*
318 *cohort study*. *Lancet*, 2021. **398**(10302): p. 747-758.
- 319 3. Coronavirus disease (COVID-19): Post COVID-19 condition. World Health
320 Organization.
321 [https://www.who.int/news-room/questions-and-answers/item/coronavirus-disease-\(covi](https://www.who.int/news-room/questions-and-answers/item/coronavirus-disease-(covid-19)-post-covid-19-condition)
322 [d-19\)-post-covid-19-condition](https://www.who.int/news-room/questions-and-answers/item/coronavirus-disease-(covid-19)-post-covid-19-condition) [accessed 7 May 2022]
- 323 4. Long COVID or Post-COVID Conditions. Centers for Disease Control and Prevention.
324 <https://www.cdc.gov/coronavirus/2019-ncov/long-term-effects/index.html#:~:text=Heal>
325 [th%20conditions&text=Some%20people%2C%20especially%20those%20who,kidney](https://www.cdc.gov/coronavirus/2019-ncov/long-term-effects/index.html#:~:text=Heal)
326 [%2C%20skin%2C%20and%20brain.](https://www.cdc.gov/coronavirus/2019-ncov/long-term-effects/index.html#:~:text=Heal) [accessed 7 May 2022]
- 327 5. Carfi, A., R. Bernabei, and F. Landi, *Persistent Symptoms in Patients After Acute*
328 *COVID-19*. *Jama*, 2020. **324**(6): p. 603-605.

- 329 6. Huang, C., et al., *6-month consequences of COVID-19 in patients discharged from*
330 *hospital: a cohort study*. Lancet, 2021. **397**(10270): p. 220-232.
- 331 7. Menni, C., et al., *Symptom prevalence, duration, and risk of hospital admission in*
332 *individuals infected with SARS-CoV-2 during periods of omicron and delta variant*
333 *dominance: a prospective observational study from the ZOE COVID Study*. Lancet,
334 2022. **399**(10335): p. 1618-1624.
- 335 8. WHO Coronavirus Dashboard. <https://covid19.who.int/>. Accessed on May 6, 2022.
- 336 9. COVID-19 Weekly Epidemiological Update, Edition 79, published 15 February 2022,
337 World Health Organization.
338 [https://reliefweb.int/sites/reliefweb.int/files/resources/20220215_Weekly_Epi_Update_](https://reliefweb.int/sites/reliefweb.int/files/resources/20220215_Weekly_Epi_Update_79.pdf)
339 [79.pdf](https://reliefweb.int/sites/reliefweb.int/files/resources/20220215_Weekly_Epi_Update_79.pdf). Accessed on May 6, 2022.
- 340 10. Nalbandian, A., et al., *Post-acute COVID-19 syndrome*. Nat Med, 2021. **27**(4): p.
341 601-615.
- 342 11. Del Rio, C., L.F. Collins, and P. Malani, *Long-term Health Consequences of COVID-19*.
343 *Jama*, 2020. **324**(17): p. 1723-1724.
- 344 12. Garrigues, E., et al., *Post-discharge persistent symptoms and health-related quality of*
345 *life after hospitalization for COVID-19*. J Infect, 2020. **81**(6): p. e4-e6.

- 346 13. Tenforde, M.W., et al., *Symptom Duration and Risk Factors for Delayed Return to*
347 *Usual Health Among Outpatients with COVID-19 in a Multistate Health Care Systems*
348 *Network - United States, March-June 2020*. MMWR Morb Mortal Wkly Rep, 2020.
349 **69**(30): p. 993-998.
- 350 14. Ahmad, I. and F.A. Rathore, *Neurological manifestations and complications of*
351 *COVID-19: A literature review*. J Clin Neurosci, 2020. **77**: p. 8-12.
- 352 15. Antonelli, M., et al., *Risk factors and disease profile of post-vaccination SARS-CoV-2*
353 *infection in UK users of the COVID Symptom Study app: a prospective,*
354 *community-based, nested, case-control study*. Lancet Infect Dis, 2021.
- 355 16. Miyazato, Y., et al., *Prolonged and Late-Onset Symptoms of Coronavirus Disease 2019*.
356 Open Forum Infect Dis, 2020. **7**(11): p. ofaa507.
- 357 17. Sudre, C.H., et al., *Attributes and predictors of long COVID*. Nat Med, 2021. **27**(4): p.
358 626-631.
- 359 18. Antonelli, M., et al., *Risk factors and disease profile of post-vaccination SARS-CoV-2*
360 *infection in UK users of the COVID Symptom Study app: a prospective,*
361 *community-based, nested, case-control study*. Lancet Infect Dis, 2022. **22**(1): p. 43-55.
- 362 19. Ho D et al. (2011) Matchit: nonparametric preprocessing for parametric causal
363 inference. Journal of Statistical Software 42, 1–28.

- 364 20. Centers for Disease Control and Prevention. SARS-CoV-2 Variant Classifications and
365 Definitions,
366 <https://www.cdc.gov/coronavirus/2019-ncov/variants/variant-classifications.html>
367 [accessed 7 May 2022].
- 368 21. Shrotri, M., et al., *Spike-antibody waning after second dose of BNT162b2 or ChAdOx1*.
369 *Lancet*, 2021. **398**(10298): p. 385-387.
- 370 22. Hui, K.P.Y., et al., *SARS-CoV-2 Omicron variant replication in human bronchus and*
371 *lung ex vivo*. *Nature*, 2022. **603**(7902): p. 715-720.
- 372 23. Ministry of Health, Labour and Welfare. Number of domestic cases of variants of
373 SARS-CoV-2 of concern by prefecture (genomic analysis),
374 https://www.mhlw.go.jp/stf/seisakunitsuite/newpage_00054.html [accessed 7 May
375 2022]
- 376 24. Centers for Disease Control and Prevention. SARS-CoV-2 Variant Classifications and
377 Definitions,
378 <https://www.cdc.gov/coronavirus/2019-ncov/variants/variant-classifications.html>
379 [accessed 7 May 2022].
- 380 25. Coronavirus Pandemic (COVID-19). <https://ourworldindata.org/coronavirus>. [accessed
381 7 May 2022]

384 **Table 1.** Characteristics of the participants in the Omicron group and the control group before matching

385

386	Characteristics	Omicron group	Control group	SMD	p-value ^a
387		(n=53)	(n=502)		
388	Age, median (IQR), years	56.0 (35.0, 69.5)	48.0 (42.0, 55.0)		0.011
389	Older adult ^b , No. (%)	17 (32.1) ^c	24 (4.8)	0.767	<0.001
390	Female sex, No. (%)	14 (26.4)	300 (59.8)	0.714	<0.001
391	BMI ^d , median (IQR)	24.4 (22.2, 26.8)	23.1 (20.7, 25.9)		0.045
392	Obesity ^e , No. (%)	23 (43.4)	150 (30.0)	0.281	0.045
393	Ethnicity, No. (%)				
394	Japanese	44 (83.0)	502 (100)		
395	Asian	4 (7.5)	0 (0.0)		
396	Caribbean	3 (5.7)	0 (0.0)		
397	African	2 (3.8)	0 (0.0)		
398	Smoking history, No. (%)				
399	Yes	25 (50.0)	206 (41.0)		0.225
400	Individual comorbidities, No. (%)				
401	No medical conditions	27 (50.9)	234 (49.9)		0.885

402	Hypertension	10 (18.9)	70 (14.9)		0.450
403	Dyslipidemia	10 (18.9)	59 (12.6)		0.200
404	Diabetes	4 (7.5)	19 (4.1)		0.277
405	COPD	1 (1.9)	2 (0.4)		0.275
406	Bronchial asthma	3 (5.7)	69 (14.7)		0.700
407	Myocardial infarction	1 (1.9)	0 (0.0)		0.102
408	Malignancy	8 (15.1)	11 (2.3)		<0.001
409	Immunodeficiency	1 (1.9)	2 (0.4)		0.275
410	Chronic kidney disease	2 (3.8)	2 (0.4)		0.053
411	Vaccination ^f , No. (%)	45 (84.9)	11 (2.2)	2.994	<0.001
<hr/>					
412	Acute COVID-19 characteristics, No. (%)				
413	Pneumonia diagnosed	12 (22.6)	141 (33.3)		0.214
414	Severity ^g				0.173
415	Mild	42 (79.2)	393 (86.4)		
416	Moderate	11 (20.8)	58 (12.7)		
417	Severe	0 (0.0)	4 (0.9)		
418	Pharmacological treatments				
419	Antiviral	13 (24.5)	56 (13.0)		0.020

420	Corticosteroids	12 (22.6)	58 (13.6)	0.067
421	mAb ^h	13 (24.5)	4 (0.8)	<0.001

422 Abbreviations: SMD, standardized mean difference; BMI, body mass index; IQR, interquartile
423 range; COPD, chronic obstructive pulmonary disease; COVID-19, coronavirus disease 2019;
424 IMV, invasive mechanical ventilation.

425 ^aMann–Whitney U test for continuous variables, Fisher’s exact test or Kruskal–Wallis test for
426 categorical variables.

427 ^bOlder adult is defined as age of 65 or more.

428 ^cThe denominator in each category depends on the number of missing values.

429 ^dCalculated as weight in kilograms divided by height in meters squared.

430 ^eObesity is defined as BMI of 25 or more.

431 ^fPatients tested positive for SARS-CoV-2 at least 7 days after their second vaccination when
432 immunity had developed

433 ^gHighest severity during clinical course of COVID-19

434 ^hMonoclonal antibodies were either casirivimab/imdevimab or sotrovimab.

435

436 **Table 2.** Characteristics of the participants in the Omicron group and the control group after matching

437

438	Characteristics	Omicron group	Control group	SMD	p-value ^a
439		(n=18)	(n=18)		
440	Age, median (IQR), years	37.5 (30.8, 66.5)	52.0 (46.5, 61.3)		0.239
441	Older adult ^b , No. (%)	4 (22.2) ^c	4 (22.2)	<0.001	1.000
442	Female sex, No. (%)	10 (55.6)	10 (55.6)	<0.001	1.000
443	BMI ^d , median (IQR)	23.3 (21.0, 24.9)	23.3 (21.8, 25.1)		0.696
444	Obesity ^e , No. (%)	5 (27.8)	5 (27.8)	<0.001	1.000
445	Ethnicity, No. (%)				
446	Japanese	12 (66.7)	18 (100)		
447	Asian	2 (11.1)	0 (0.0)		
448	Caribbean	2 (11.1)	0 (0.0)		
449	African	2 (11.1)	0 (0.0)		
450	Smoking history, No. (%)				
451	Yes	7 (41.2)	10 (55.6)		0.395
452	Individual comorbidities, No. (%)				
453	No medical conditions	12 (66.7)	9 (50.0)		0.310

454	Hypertension	1 (5.6)	3 (16.7)		0.603
455	Dyslipidemia	2 (11.1)	3 (16.7)		1.0
456	Diabetes	1 (5.6)	2 (11.1)		1.0
457	COPD	0 (0.0)	1 (5.6)		1.0
458	Bronchial asthma	1 (5.6)	5 (27.8)		0.177
459	Myocardial infarction	0 (0.0)	0 (0.0)		1.00
460	Malignancy	3 (16.7)	0 (0.0)		0.229
461	Immunodeficiency	0 (0.0)	0 (0.0)		1.0
462	Chronic kidney disease	0 (0.0)	0 (0.0)		1.0
463	Vaccination ^f , No. (%)	10 (55.6)	10 (55.6)	<0.001	1.0
<hr/>					
464	Acute COVID-19 characteristics, No. (%)				
465	Pneumonia diagnosed	4 (22.2)	4 (23.5)		1.0
466	Severity ^g				0.635
467	Mild	16 (88.9)	15 (83.3)		
468	Moderate	2 (11.1)	3 (16.7)		
469	Severe	0 (0.0)	0 (0.0)		
470	Pharmacological treatments				
471	Antiviral	3 (16.7)	1 (5.6)		0.603

472	Corticosteroids	2 (11.1)	4 (22.2)	0.658
473	mAb ^h	3 (16.7)	1 (5.6)	0.603

474 Abbreviations: SMD, standardized mean difference; BMI, body mass index; IQR, interquartile
475 range; COPD, chronic obstructive pulmonary disease; COVID-19, coronavirus disease 2019;
476 IMV, invasive mechanical ventilation.

477 ^aMann–Whitney U test for continuous variables, Fisher’s exact test or Kruskal–Wallis test for
478 categorical variables.

479 ^bOlder adult is defined as age of 65 or more.

480 ^cThe denominator in each category depends on the number of missing values.

481 ^dCalculated as weight in kilograms divided by height in meters squared.

482 ^eObesity is defined as BMI of 25 or more.

483 ^fPatients tested positive for SARS-CoV-2 at least 7 days after their second vaccination when
484 immunity had developed

485 ^gHighest severity during clinical course of COVID-19

486 ^hMonoclonal antibodies were either casirivimab/imdevimab or sotrovimab.

487

488 **Table 3.** The number of participants with post COVID-19 condition in the Omicron group

489 (n=53)

Symptoms	Number ^a (% ^b)	Lasting at least 2 months within 3 months since the onset (% ^b)
Fatigue	22 (41.5)	3 (5.7)
SoB	10 (18.9)	2 (3.8)
Cough	23 (43.4)	2 (3.8)
Dysosmia	3 (5.7)	0 (0.0)
Dysgeusia	7 (13.2)	0 (0.0)
Hair loss	2 (3.8)	0 (0.0)
Depressed mood	5 (9.4)	2 (3.8)
Brain fog	0 (0.0)	0 (0.0)
LoC	8 (15.1)	3 (5.7)
MD	3 (5.7)	1 (1.9)
At least one symptom ^c	41 (77.4)	7 (13.2)

Other symptoms

Fever	45 (84.9)	0 (0.0)
Sore throat	30 (56.6)	0 (0.0)
Sputum	19 (35.8)	2 (3.8)
Runny nose	15 (28.3)	0 (0.0)
Headache	10 (18.9)	1 (1.9)
Muscle pain	1 (1.9)	0 (0.0)
Joint pain	7 (13.2)	0 (0.0)
Chest pain	3 (5.7)	1 (1.9)
Palpitation	1 (1.9)	1 (1.9)
Abdominal pain	4 (7.5)	0 (0.0)
Diarrhea	6 (11.3)	0 (0.0)
Appetite loss	3 (5.7)	0 (0.0)

490 Abbreviations: SoB, shortness of breath; LoC, loss of concentration; MD, memory disturbance.

491 ^a Number of patients experiencing each symptom within 3 months since the onset

492 ^b Calculated by dividing the number of patients by the total number of participants (n = 53).

493 ^c At least one symptom of fatigue, shortness of breath, cough, dysosmia, dysgeusia, hair loss,

494 depressed mood, brain fog, loss of concentration, and memory disturbance (not including other

495 symptoms)

496

497 **Table 4.** Prevalence of post COVID-19 condition in the Omicron group and the control group

Symptoms ^a	Omicron group (n=18)	Control group (n=18)	p-value ^b
Fatigue	1 (5.6)	1 (5.6)	1.0
SoB	0 (0.0)	1 (5.6)	1.0
Cough	0 (0.0)	3 (16.7)	0.229
Dysosmia	0 (0.0)	3 (16.7)	0.229
Dysgeusia	0 (0.0)	1 (5.6)	1.000
Hair loss	0 (0.0)	3 (16.7)	0.229
Depressed mood	0 (0.0)	0 (0.0)	1.0
Brain fog	0 (0.0)	1 (5.6)	1.0
LoC	0 (0.0)	1 (5.6)	1.0
MD	0 (0.0)	2 (11.1)	0.486
At least one post-acute	1 (5.6)	10 (55.6)	0.003

COVID-19 symptom

498 Abbreviations: SoB, shortness of breath; LoC, loss of concentration; MD, memory disturbance.

499 ^aDefinition of post COVID-19 condition is a symptom that last at least 2 months within 3

500 months since the onset of COVID-19.

501 ^bResults of Fisher's exact test.

502

503

504 **Figure Legends**

505 **Figure 1.** The frequency and duration of at least one symptom in the Omicron group and

506 the control group after matching

507 **Appendix 4.** The frequency and duration of each symptom in the Omicron group

508 **Appendix 5.** The frequency and duration of each symptom in the control group

509

